Latest Articles
-
What’s Happening With MRK Stock?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, compared to the consensus estimates of $15.5...
-
What’s New With Merck?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly stock (up 31%) and AbbVie stock (up 15%), ...
-
What’s Next For Merck Stock After An Upbeat Q3?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share, compared to the consensus estimates of $16.5 billion ...
-
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period. This can primarily be attributed to a signif...
-
Is Merck Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock (NYSE:ABBV). MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor...
-
Should You Pick Merck Stock At $115 After A Q2 Beat?
Merck (NYSE: MRK) recently reported its Q2 results, with revenues and earnings exceeding our estimates . The company garnered $16.1 billion in revenue and adjusted earnings of $2.28 per share, compared to our estimates of $15.9 billion and $2....
-
Is An Earnings Beat In The Cards For Merck Stock?
Merck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates. As usual, Keytruda will be driving the growth ...
-
With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?
We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK) . The decision to invest often comes down to finding the best stocks within the scope of certain characteristics...
-
Is Johnson & Johnson Stock A Better Pick Over Merck?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK) . Although Merck trades at a higher valuation of 5.5x trailing revenues, compared to 4.2 x for J&J,...
-
Is Merck Stock Fully Valued At $130?
Merck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates . The company garnered $15.8 billion in revenue and adjusted earnings of $2.07 per share, compared to our estimates of $15.2 billion and $1....
-
Will Higher Keytruda Sales Drive Merck’s Q1
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates. As usual, Keytruda will be the driving growt...
-
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth ov...
-
At $100 Does Merck Stock Have Room For Growth?
Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth, as discussed below. The company reported revenue of $16.0 billion and adjus...
-
Should You Pick Merck Stock Over Coca-Cola?
We believe that Merck stock (NYSE: MRK) and Coca-Cola stock (NYSE: KO) will offer little returns in the next three years. Although these companies are from different sectors, we compare them because they have a similar market capitalization...
-
Should You Buy Merck Stock After An Upbeat Q2?
Merck stock (NYSE: MRK), after an 8% fall in a month, underperforming the broader markets, with the S&P500 up 3%, appears to have room for growth. The company posted upbeat Q2 results this week, with solid growth for Keytruda and Gardasil. ...
